CJC-1295 No DAC Questions, Answered

This page brings together the questions most often asked about CJC-1295 no DAC and answers them from what published peptide research and product documentation actually report. It covers how the modified and unmodified versions of the molecule differ, what growth hormone pulse and rhythm studies have described, how the compound is characterized when paired with Ipamorelin in animal work, what the regulatory and approval picture looks like heading into 2026, and how laboratories structure repeated-exposure study designs. Every compound discussed here is a research chemical supplied strictly for research use only, and nothing below is a recommendation for anything outside laboratory contexts.

What CJC-1295 No DAC Is and How It Differs From the DAC Version

CJC-1295 no DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH), built from the first twenty-nine amino acids of the native hormone with a small number of substitutions that slow enzymatic breakdown. It is frequently listed in catalogues and literature under the name modified GRF (1-29), and the two terms describe the same peptide. Like native GHRH, it binds the GHRH receptor on somatotroph cells of the anterior pituitary and prompts those cells to release stored growth hormone.

The difference between the two CJC-1295 variants is the Drug Affinity Complex, or DAC. The DAC-modified version carries a maleimide group that binds covalently to circulating serum albumin, which shelters the peptide from clearance and stretches its presence in plasma from minutes to days. The unmodified version has no such anchor. Its circulating life is short — measured in tens of minutes rather than days — which is precisely why it is selected for certain experimental questions.

Researchers describe the practical consequence this way: the DAC version produces a prolonged, relatively flat elevation in growth hormone and downstream IGF-1, often called a "bleed" of hormone rather than a pulse. The no-DAC version produces a discrete, short-lived amplification of a single secretory episode and then clears. Investigators studying tonic hormone elevation tend to select the DAC form; investigators studying pulsatility, feedback, or timing-sensitive endpoints tend to select the no-DAC form. Neither is a superior molecule in the abstract — they answer different questions.

What Research Reports About Natural Growth Hormone Rhythm

The published rationale for using CJC-1295 no DAC in rhythm-focused work is that it amplifies existing secretory episodes rather than overwriting them. Endogenous growth hormone in mammals is not released continuously; it emerges in bursts governed by an interplay between GHRH, ghrelin signalling, and somatostatin, the inhibitory hormone that closes the secretory window. Because the no-DAC peptide clears quickly, somatostatin tone is still able to terminate a burst on its normal schedule, and the underlying architecture of the rhythm remains recognizable in sampling data.

This is the central distinction investigators draw between a secretagogue approach and exogenous recombinant growth hormone. Administered hormone raises circulating levels directly and suppresses the pituitary's own output through negative feedback. A short-acting GHRH analogue works upstream: the pituitary still decides when to fire, how much is available in the releasable pool, and how feedback signals modulate the next episode. Studies that track serial blood sampling in animal models describe preserved burst-and-trough patterning under short-acting analogue exposure, in contrast to the flattened profiles seen with long-acting agents.

Literature describing rhythm-focused designs generally reports that laboratories time administration to coincide with periods of low somatostatin tone, and that repeated small exposures spaced across the day are used more often than single large ones, because the aim is to reinforce natural episodes rather than create artificial ones. The magnitude of that reinforcement varies considerably between species, ages, and study conditions, and the literature on rhythm preservation in humans outside laboratory contexts is genuinely thin — most of what is described comes from animal work and short controlled pharmacology studies.

What Research Reports About Growth Hormone Pulse Studies

CJC-1295 no DAC is a common tool in pulse-focused investigation because its kinetics roughly match the duration of a natural secretory burst. Researchers examining questions such as pulse amplitude versus pulse frequency, the role of trough depth in downstream signalling, or how circadian phase alters pituitary responsiveness need a stimulus that begins and ends quickly. A compound with a multi-day presence in plasma cannot resolve those questions because it collapses discrete events into a continuous signal.

Published pharmacology consistently describes dose-dependent increases in growth hormone following GHRH analogue exposure, with the response constrained by how much hormone the somatotrophs have stored and by prevailing somatostatin tone. This ceiling effect is itself a frequent subject of study: it explains why increasing the amount administered eventually stops producing proportionally larger bursts, and why several laboratories pair a GHRH analogue with a ghrelin-receptor agonist to test whether the two mechanisms combine.

For circadian questions, the short-acting version is generally preferred precisely because it does not persist into subsequent phases of the light-dark cycle. Investigators examining whether nocturnal secretory episodes differ mechanistically from daytime ones can apply a stimulus in one phase and sample in another without residual compound confounding the comparison. Published work in this area is descriptive and largely preclinical; broad conclusions about circadian modulation in humans remain under-supported by the available evidence.

What Research Reports About Pairing CJC-1295 No DAC With Ipamorelin

Ipamorelin is a selective growth hormone secretagogue receptor agonist — a ghrelin mimetic — that acts on a different pituitary receptor than CJC-1295 no DAC. The frequently described rationale for studying them together is mechanistic complementarity: the GHRH analogue increases the amount of hormone released per secretory event, while the ghrelin-receptor agonist both stimulates release and suppresses somatostatin, effectively lifting the brake that would otherwise limit the burst.

Published work on this pairing reports that the combined stimulus produces a larger growth hormone response than either compound alone in the models examined, which is the primary reason the two appear together in so many catalogue listings and study designs. Ipamorelin is further described in the literature as notably selective, with minimal reported effect on cortisol and prolactin compared with earlier secretagogues such as GHRP-6 — a property that matters experimentally, because it reduces the number of confounding hormonal variables in a study.

Documentation on the pairing typically describes both peptides supplied as lyophilized powder, reconstituted with bacteriostatic water, and stored refrigerated after reconstitution. Researchers considering this combination are generally those investigating pituitary signalling architecture, IGF-1 axis behaviour, body composition endpoints in animal models, or recovery and connective tissue markers. It is not a combination with an established profile in any approved medical context.

What Research Reports About Lean Mass and IGF-1 Markers in Animal Models

Growth hormone secretagogues are studied in muscle research because growth hormone drives hepatic IGF-1 production, and IGF-1 is a well-characterized mediator of myocyte hypertrophy, satellite cell activation, and protein synthesis signalling. The published chain of reasoning is indirect by design: the peptides do not act on muscle tissue, they act on the pituitary, and any effect on tissue is downstream of the resulting hormone exposure.

In rodent models, these compounds are used routinely. Published preclinical work describes endpoints including lean mass measurement, muscle fibre cross-sectional area, and circulating IGF-1, with researchers reporting measurable elevations in IGF-1 emerging over a period of days to weeks of repeated exposure rather than immediately. Acute growth hormone elevation is detectable within a short window after administration, but IGF-1 is a slower, integrative marker — it reflects cumulative hormone exposure, and single-event measurements are generally considered uninformative for that endpoint.

What the literature does not support is a clean quantitative claim about muscle accrual attributable to these peptides. Preclinical results vary with species, strain, age, nutritional status, and whether a loading stimulus is applied concurrently. Controlled work examining lean tissue outcomes from GHRH analogue and ghrelin mimetic combinations in humans is limited, and the gap between pituitary pharmacology and tissue-level outcome remains one of the more honestly unresolved areas in this field.

What Research Reports About Aged Models and Declining Endogenous Secretion

Age-related decline in growth hormone secretion — sometimes described as somatopause — is one of the more common experimental applications for short-acting GHRH analogues, and the reason is mechanistic. Published characterization of the aging neuroendocrine axis indicates that the decline is driven substantially by reduced hypothalamic GHRH output and altered somatostatin tone rather than by exhaustion of the pituitary's capacity to produce hormone. Somatotroph cells in aged models generally retain a releasable pool.

That distinction makes a secretagogue approach experimentally interesting in aged cohorts: a GHRH-receptor stimulus can test whether the pituitary still responds, and how that responsiveness compares with younger controls. Investigators use this as a probe of where in the axis the age-related change resides. Because a short-acting analogue does not suppress endogenous signalling the way exogenous hormone does, studies can also examine whether residual natural rhythm persists alongside the stimulated response.

Researchers consistently frame this as studying the aging axis, not as restoring youthful hormone levels. Published findings describe attenuated but present responsiveness in older animals, with substantial individual variability. Claims that any peptide restores a youthful secretory profile are not supported by the available evidence.

What Research Reports About Receptor Responsiveness Over Extended Studies

The question of whether CJC-1295 no DAC should be studied in interrupted blocks rather than continuously comes down to receptor behaviour. GHRH receptors, like many G-protein-coupled receptors, are described in the literature as subject to downregulation and desensitization under sustained agonist pressure, and somatostatin feedback strengthens in response to elevated growth hormone and IGF-1. Both mechanisms would tend to blunt response over time.

This is why many published designs use defined exposure blocks separated by intervals with no compound present, and why the short clearance of the no-DAC form is sometimes described as partially self-limiting — because plasma levels fall to baseline between events, receptors experience intermittent rather than continuous occupancy. Some investigators argue this means shorter breaks are sufficient compared with the DAC version, which maintains near-continuous receptor engagement. The literature does not establish a single correct interval, and reported washout periods in study designs vary widely.

Low continuous exposure is sometimes proposed as an alternative to interrupted designs on the theory that a smaller stimulus provokes less adaptive resistance. Evidence for that proposition is weak. What the literature reports more reliably is that response magnitude tends to drift downward under prolonged uninterrupted stimulation, and that re-establishing responsiveness requires a period of absence. Laboratories typically confirm this empirically within their own model rather than assuming a fixed rule.

What Documentation Reports About Legal and Approval Status in 2026

Neither CJC-1295 no DAC nor Ipamorelin holds marketing approval from the US Food and Drug Administration for any medical indication, and that remains the case entering 2026. Both are investigational compounds. Ipamorelin was evaluated in clinical development and did not advance to approval; CJC-1295 in either form has never carried an approved indication. Tesamorelin is the GHRH analogue that did reach approval, for a narrow indication, and it is a distinct molecule.

In the United States these peptides are not scheduled controlled substances at the federal level, but they are unapproved drugs, which means they may not be marketed or distributed for therapeutic purposes. They are supplied lawfully as research chemicals, labelled research use only, and not for diagnostic, therapeutic, or veterinary application. Regulatory agencies have taken an increasingly restrictive posture toward compounded peptide preparations, placing several growth hormone secretagogues in categories that effectively bar compounding pharmacies from producing them. Prescribing pathways are correspondingly narrow and jurisdiction-dependent.

Both compounds appear on the World Anti-Doping Agency prohibited list as growth hormone secretagogues, banned at all times in tested sport. Import rules, national drug schedules, and enforcement priorities differ substantially between countries, and status can change without notice. Purchasers acquiring these materials for laboratory work are responsible for verifying the rules that apply in their own jurisdiction and institution.

What Documentation Reports About Purity, Handling, and Cost Factors

Research-grade CJC-1295 no DAC and Ipamorelin are typically supplied as lyophilized powder in sealed vials, most commonly in single-digit milligram quantities, with accompanying analytical documentation. Purity verification by high-performance liquid chromatography and identity confirmation by mass spectrometry are the standard expectations, and reputable suppliers make batch-specific certificates of analysis available rather than generic documentation.

Pricing varies with peptide length and synthesis difficulty, vial size, purity threshold, whether third-party testing is included, and order volume. CJC-1295 no DAC is a twenty-nine-residue peptide and is generally more costly to synthesize than Ipamorelin, a much shorter pentapeptide. Kits bundling both compounds are commonly listed at a lower combined price than separate purchase. Unusually low pricing is frequently flagged in supplier guidance as a signal of under-filled vials, degraded material, or absent analytical verification.

Handling documentation describes lyophilized material as stable under refrigeration or freezing when protected from light and moisture, with reconstituted solution kept refrigerated and used within a limited window. Repeated freeze-thaw cycles of reconstituted peptide are consistently described as degrading. These are laboratory storage practices, not instructions for any application outside a research setting.